Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997503 · ClinicalTrials.gov registry record
TAXUS Libertē Post Approval Study
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 4,199
- Enrollment target
NCT00997503: Completed study, sponsored by Boston Scientific Corporation.
NCT00997503 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 4,199 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00997503 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 4,199 participants
- Enrollment target
Study Summary
The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).
Primary Outcome
Cardiac death or myocardial infarction in the TAXUS Liberte Post-Approval Study enrolled population. For pooled data from the TAXUS Liberté and TAXUS Express patient populations, please see the citations.
Interventions
- DRUG placebo
- DRUG aspirin
- DRUG prasugrel
- DEVICE TAXUS Liberté Paclitaxel-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,199 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-07 |
What the finished NCT00997503 record still lists
NCT00997503 is an observational study that tracks outcomes without assigning an intervention. Its 4,199 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00997503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00997503 about?
NCT00997503 is a clinical study titled "TAXUS Libertē Post Approval Study". The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAP...
What is the current status of trial NCT00997503?
This trial is currently completed. The enrollment target is 4,199 participants. The study started on 2009-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00997503?
The interventions under investigation include: placebo (DRUG), aspirin (DRUG), prasugrel (DRUG), TAXUS Liberté Paclitaxel-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00997503?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
- NCT06935370 · 4,200 participants · Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- NCT07209098 · 4,200 participants
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia